Leukemias, lymphomas, and other hematologic cancers:

Indications for Idarubicin:

Acute myeloid leukemia, in combination with other antileukemic drugs.

Adult Dosage:

Give by slow IV infusion (over 10–15mins). 12mg/m2 daily for 3 days (in combination with cytarabine). May give 2nd course if needed; if toxicity develops after 1st course, delay until resolved; reduce dose by 25%. Hepatic and renal impairment: consider reduce dose.

Children Dosage:

Not established.

Boxed Warning:

Extravasation. Myocardial toxicity. Severe myelosuppression. Hepatic or renal impairment.

Idarubicin Warnings/Precautions:

Administer under the supervision of an experienced physician. Avoid in pre-existing bone marrow suppression. Increased risk of myocardial toxicity in pre-existing cardiovascular disease, previous anthracycline therapy at high cumulative doses, concomitant or previous mediastinal pericardial irradiation, anemia, bone marrow suppression, infections, leukemic pericarditis and/or myocarditis. Monitor CBCs, cardiac, hepatic and renal function prior to and during treatment. Monitor for hyperuricemia, infections. Hepatic or renal impairment (see Adults). Avoid extravasation. Elderly. Pregnancy: avoid. Advise to use effective contraception during and for ≥6.5 months (females of reproductive potential) or for ≥3.5 months (males w. female partners) after the last dose. Nursing mothers: not recommended.

See Also:

Idarubicin Classification:


Idarubicin Interactions:

Concomitant drugs that suppress cardiac contractility or cardiotoxic drugs (eg, trastuzumab, cyclophosphamide, paclitaxel): not recommended; avoid use for at least 5 half-lives after discontinuing cardiotoxic drug (up to 7mos for trastuzumab).

Adverse Reactions:

Myelosuppression (may be severe), GI upset, mucositis, abdominal pain, alopecia, rash, inj site reactions, cardiotoxicity (eg, CHF, arrhythmias, chest pain, MI, asymptomatic declines in LVEF).

How Supplied:

Single-dose vials—contact supplier; PFS: Single-dose vials (5mL, 10mL, 20mL)—1